Zydus Lifesciences posts 30% revenue jump in Q3, net profit up 9%

Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in revenue from operations to ₹68,645 million for the third quarter ended December 31, 2025, driven by strong performance across its pharmaceutical, consumer wellness and medtech businesses.

The company’s adjusted net profit for the quarter rose 9 per cent to ₹11,109 million, while EBITDA grew 31 per cent to ₹18,164 million with margins improving 20 basis points to 26.5 per cent.

The Ahmedabad-based pharmaceutical company’s North America formulations business, which accounts for 41 per cent of consolidated revenues, posted 16 per cent growth to ₹28,043 million.

The US division launched four new products and received eight ANDA approvals during the quarter. In January 2026, the company received USFDA approval for Zycubo, the first approved therapy for Menkes disease, an ultra-rare condition.

India formulations grew 13 per cent year-on-year to ₹17,094 million, outpacing market growth with branded business expansion of 14 per cent. The chronic segment portfolio now represents 45.3 per cent of the India business, up 560 basis points over three years. International markets formulations surged 38 per cent to ₹7,881 million on broad-based demand across emerging markets and Europe.

Consumer wellness revenues jumped 113 per cent to ₹9,578 million, reflecting the full quarter consolidation of Comfort Click Limited, which the company acquired earlier. The newly added medtech segment contributed ₹2,996 million following the acquisition of Amplitude Surgical’s business. For the nine-month period, total revenues reached ₹195,614 million, up 17 per cent year-on-year, with adjusted net profit rising 15 per cent to ₹38,640 million.

The company’s net debt to equity ratio stood at 0.11 times as of December 31, 2025, with net debt of ₹28,728 million compared to negative net debt of ₹48,880 million in March 2025. Research and development investments for the quarter were ₹6,074 million, representing 8.8 per cent of revenues.

Shares of Zydus Lifesciences were trading at ₹918.15 on the NSE as of 2:11 pm on Monday, up ₹30 or 3.38 per cent from the previous close of ₹888.15. The stock hit an intraday high of ₹933.35 and low of ₹884.00, with traded volume of 15.81 lakh shares.

Published on February 9, 2026